C. Williams

发表

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane

H. Gabra, P. Vasey, S. Kaye, 2013 .

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.

G. Rustin, H. Gabra, P. Vasey, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4).

G. Rustin, H. Gabra, P. Vasey, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.

N. Russell, M. Gilyead, M. Bishton, 2007, Leukemia research.

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Jonathon P. Baker, F. Hayden, W. Greenhalf, 2022, The Lancet Infectious Diseases.

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.

D. Johnston, D. Osoba, F. Shepherd, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

D. Tu, V. Bramwell, B. Norris, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies

S. Akinaga, P. Johnson, J. Cavenagh, 2015, British Journal of Cancer.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

G. Morgan, W. Gregory, M. Drayson, 2016, Blood Cancer Journal.

United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma

G. Cook, F. Davies, J. Behrens, 2009, International journal of laboratory hematology.

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.

G. Rustin, P. Vasey, Susana Banerjee, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Uptake of high‐dose therapy and peripheral blood stem cell transplantation in myeloma patients <65 years – the role of the myeloma multi‐disciplinary team

N. Russell, C. Williams, J. Byrne, 2005, British journal of haematology.